A W Partin

发表

Quantitative nuclear grade (QNG): A new image analysis‐based biomarker of clinically relevant nuclear structure alterations

R W Veltri, A W Partin, M C Miller, 2000, Journal of cellular biochemistry. Supplement.

Exploratory data analysis groupware for qualitative and quantitative electrophoretic gel analysis over the Internet‐WebGel

A W Partin, P F Lemkin, J M Myrick, 1999, Electrophoresis.

The clinical usefulness of percent free-PSA.

A W Partin, J. Oesterling, A. Partin, 1996, Urology.

Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma.

A W Partin, J W Simons, F. Marshall, 1999, Urology.

Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI‐TOF

R W Veltri, A W Partin, A. Partin, 2004, The Prostate.

Detection of intact prostate cancer cells in the blood of men with prostate cancer.

A W Partin, J. Pannek, A. Partin, 1997, Urology.

Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy.

R W Veltri, A W Partin, A. Partin, 1999, Urology.

The problem of cutoff levels in a screened population

G Bartsch, A W Partin, A. Partin, 2001, Cancer.

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.

A W Partin, M W Kattan, M. Kattan, 1997, JAMA.

Fourier analysis of cell motility: correlation of motility with metastatic potential.

A W Partin, A. Partin, D. S. Coffey, 1989, Proceedings of the National Academy of Sciences of the United States of America.

A comparison of nuclear morphometry and Gleason grade as a predictor of prognosis in stage A2 prostate cancer: a critical analysis.

A W Partin, A. Partin, D. S. Coffey, 1989, The Journal of urology.

Disease progression following radical prostatectomy in men with Gleason score 7 tumor.

A W Partin, A. Partin, P. Walsh, 1998, The Journal of urology.

Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer.

A W Partin, E J Gamito, A. Partin, 2001, Urology.

Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. II. Standardization of methodology for histologic sections.

A W Partin, A. Partin, D. S. Coffey, 1988, The Journal of urology.

Nuclear roundness factor measurement for assessment of prognosis of patients with prostatic carcinoma. I. Testing of a digitization system.

A W Partin, A. Partin, D. S. Coffey, 1988, The Journal of urology.

Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer.

A W Partin, A. Partin, D. S. Coffey, 1993, Cancer research.

Natural history of progression after PSA elevation following radical prostatectomy.

A W Partin, D. Chan, A. Partin, 1999, JAMA.

The role of PSA and percent free PSA for staging and prognosis prediction in clinically localized prostate cancer.

A W Partin, J. Pannek, A. Partin, 1998, Seminars in urologic oncology.

Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer.

G Bartsch, A W Partin, A. Partin, 2001, Urology.

Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup.

A W Partin, A. Partin, P. Walsh, 1993, The Journal of urology.

Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei.

R W Veltri, A W Partin, A. Partin, 1996, Urology.

Comparison of robotic versus human laparoscopic camera control .

A W Partin, L R Kavoussi, Robert G. Moore, 1995, The Journal of urology.

New laparoscopic suturing device: initial clinical experience.

A W Partin, L R Kavoussi, P G Schulam, 1995, Urology.

The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma

A W Partin, E D Crawford, E J Gamito, 2000, Cancer.

The rat as a model for the study of penile erection.

A W Partin, A. Partin, P. Walsh, 1989, The Journal of urology.

Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.

R W Veltri, A W Partin, A. Partin, 1994, Journal of cellular biochemistry. Supplement.

Family history facilitates the early diagnosis of prostate carcinoma

A W Partin, A. Partin, P. Walsh, 1997, Cancer.

Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy.

A W Partin, A. Partin, P. Walsh, 2000, Urology.

Identification and characterization of circulating prostate carcinoma cells

A W Partin, A. Partin, H. Scher, 2000, Cancer.

Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium.

A W Partin, A. Partin, P. Walsh, 2002, Urology.

Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer.

A W Partin, A. Partin, P. Walsh, 2001, The Journal of urology.

Bioimpedance: Novel use of a minimally invasive technique for cancer localization in the intact prostate

A W Partin, J I Epstein, W W Roberts, 1999, The Prostate.

Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years.

A W Partin, A. Partin, P. Walsh, 1993, The Urologic clinics of North America.

Prediction of prostate carcinoma stage by quantitative biopsy pathology

R W Veltri, A W Partin, A. Partin, 2001, Cancer.

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age.

A W Partin, D. Chan, W. Catalona, 1996, Urology.

Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.

A W Partin, A. Partin, P. Walsh, 1994, The Journal of urology.

Complete robot-assisted laparoscopic urologic surgery: a preliminary report.

A W Partin, L R Kavoussi, L. Kavoussi, 1995, Journal of the American College of Surgeons.

Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.

A W Partin, M W Kattan, M. Kattan, 2000, The Journal of urology.

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

A W Partin, R C Flanigan, J. Richie, 1998, JAMA.

OA-519 (fatty acid synthase) as an independent predictor of pathologic state in adenocarcinoma of the prostate.

A W Partin, A. Partin, J. Epstein, 1995, Urology.

Nuclear morphometry and prognosis in favorable histology Wilms' tumor: A prospective reevaluation.

A W Partin, N E Breslow, D M Green, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins.

A W Partin, A. Partin, D. S. Coffey, 1997, Urology.

A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy.

A W Partin, A. Partin, P. Walsh, 2000, Urology.

Differential nuclear matrix protein expression in prostate cancers: correlation with pathologic stage.

A W Partin, A. Partin, E. N. Subong, 1998, The Journal of urology.